Exclusive Online Content
Curia Expands Cell Line Development Offering With CHOZN Platform
Curia signs license agreement with MilliporeSigma to support production of proteins and antibodies….
Thaerapy BV & Resyca BV Announce Exclusive License Agreement for Soft Mist Inhaler Technology
Thaerapy BV and Resyca BV a joint venture of Medspray Pharma BV and Recipharm AB, a leader in the development of soft mist inhalers, recently announced today the signing of an exclusive license agreement for Resyca’s soft mist….
Celanese & Nanoform Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants
Celanese and Nanoform Finland Plc recently provided an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery…..
Helocyte Announces $3.22-Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (CMV) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk of CMV events in high-risk transplant recipients….
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Blue Water Biotech, Inc. recently announced the signing of an Asset Purchase Agreement with WraSer, LLC and Xspire Pharma, LLC for the purchase of six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain….
Stevanato Group Presents Versatile On-Body Delivery System Platform for a Wide Range of Injectable Therapies & for Large Delivery Volumes
The company offers the platform as a readily customizable pre-filled and pre-loaded on-body solution for drug delivery. Device development is making significant progress, with samples expected to be available in 2023…..
Quell Therapeutics Signs Collaboration, Exclusive Option & License Agreement With AstraZeneca to Develop, Manufacture & Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases
Collaboration brings together Quell’s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca’s proven development and commercial capabilities as well as its deep therapeutic area knowledge….
Axol Bioscience Collaborates With StrataStem to Deliver Stem Cell-Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
Axol Bioscience Ltd. has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples…..
Needle-Free Vaccine Delivery Platform Aims to End Frozen Storage Needs & Improve Access
aVaxziPen’s innovative vaccine delivery platform aims to improve access to vaccines by removing the need for frozen storage and enabling easier distribution and deployment….
Ajinomoto Integrates R&D Sites in Japan & Korea With Genedata Bioprocess
Genedata and Ajinomoto recently announced Ajinomoto has successfully rolled out Genedata Bioprocess® to its Korean sites, Ajinomoto Genexine, in line with….
EXCLUSIVE ONLINE CONTENT
PlaqueTec & the Babraham Institute Collaborate on Early Phase Target Discovery & Development
Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec….
Biopharmaceutical Mega M&A Deals Surge by 71% YoY During Q1 2024
Mergers and acquisitions (M&As) in the biopharmaceutical industry have rebounded with a $76.9 billion increase in total deal value seen from 2022 to 2023. In Q1 2024 alone, biopharmaceutical M&A reached a total deal value of….
ElevateBio Announces New US Patents for Lead Life Edit CRISPR Systems & Adenine Deaminases Enabling Advanced Gene Editing Techniques
ElevateBio is building a robust portfolio of patents protecting its novel technologies while the Company scales as the world’s first integrated genetic medicine foundry….
AbbVie & Gilgamesh Pharmaceuticals Announce Collaboration & Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
Collaboration to leverage AbbVie’s psychiatry expertise and Gilgamesh’s innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders….
AC Immune & Takeda Sign Exclusive Option & License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression….